| Literature DB >> 31295503 |
Roberta Censi1, Cristina Casadidio1, Alessandra Dubbini1, Manuela Cortese1, Stefania Scuri2, Iolanda Grappasonni2, Samuel Golob3, Dario Vojnovic3, Maria Giovanna Sabbieti4, Dimitrios Agas4, Piera Di Martino5.
Abstract
The purpose of this work was the development of antibacterial delivery systems for vancomycin, with potential application in the prevention or treatment of orthopedic implant infections. Previous studies have shown tandem thermal gelling and Michael addition cross-linking of hydrogels based on methacrylate, acrylate or vinylsulfone triblock copolymers of PEG-p(HPMAm-lac1-2) and thiolated hyaluronic acid. In this work we exploited these α-β unsaturated derivatives of PEG-p(HPMAm-lac1-2) triblock copolymers and used them in combination with thiolated hyaluronic acid as controlled delivery systems for vancomycin. It was found that the antibiotic was sustainably released from the hydrogel networks for at least 5 days with release kinetics depending on diffusion and dissociation of the positively charged vancomycin from the negatively charged hyaluronic acid. The release of vancomycin could be tailored mainly by HA-SH solid content and degree of thiolation. The developed hydrogels were demonstrate efficacious in preserving the structural and functional integrity of the encapsulated drug by physical immobilization within the gel network and ionic interaction with hyaluronic acid, thereby preventing vancomycin deamidation processes. Furthermore, the antimicrobial activity of vancomycin loaded hydrogels was assessed, demonstrating retention of inhibitory activity towards Staphylococcus aureus during formulation and release, with slightly increased activity of vancomycin encapsulated in hydrogels of higher HA-SH content as compared to controls.Entities:
Keywords: Controlled release; Michael addition cross-linking; Protein stability; Thermosensitive hydrogels; Vancomycin
Mesh:
Substances:
Year: 2019 PMID: 31295503 DOI: 10.1016/j.ejpb.2019.07.006
Source DB: PubMed Journal: Eur J Pharm Biopharm ISSN: 0939-6411 Impact factor: 5.571